Concise Synthesis and Biological Evaluation of 2-Aroyl-5-Amino Benzo[ b ]thiophene Derivatives As a Novel Class of Potent Antimitotic Agents

Journal of Medicinal Chemistry

Volumn 56, Issue 22, 2013, Pages 9296-9309

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Lopez Cara, Carlota ^a   Preti, Delia ^a   Aghazadeh Tabrizi, Mojgan ^a   Balzarini, Jan ^b   Bassetto, Marcella ^c   Brancale, Andrea ^c   Fu, Xian Hua ^d   Gao, Yang ^d   Li, Jun ^d   Zhang, Su Zhan ^d   Hamel, Ernest ^e   Bortolozzi, Roberta ^f   Basso, Giuseppe ^f   Viola, Giampietro ^f  

^a UNIVERSITY OF FERRARA   (Italy)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d ZHEJIANG UNIVERSITY   (China)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 METHYL 6 METHOXY 5 NITROBENZO[B]THIOPHEN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (3 METHYL 7 METHOXY 5 NITROBENZO[B]THIOPHEN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (3,4,5 TRIMETHOXYPHENYL)(3 METHYL 5 AMINOBENZO[B]THIOPHEN 2 YL)METHANONE; (3,4,5 TRIMETHOXYPHENYL)(3 METHYL 5 NITROBENZO[B]THIOPHEN 2 YL)METHANONE; (5 MINOBENZO[B]THIOPHEN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 NITROBENZO[B]THIOPHEN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (7 METHOXY 5 AMINOBENZO[B]THIOPHEN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; (7 METHOXY 5 NITROBENZO[B]THIOPHEN 2 YL)(3,4,5,TRIMETHOXYPHENYL)METHANONE; (7 METHOXY 5 NITROBENZO[B]THIOPHEN 2 YL)(4 DIMETHOXYPHENYL)METHANONE; (7 METHOXY 5 NITROBENZO[B]THIOPHEN 2 YL)(4,5 DIMETHOXYPHENYL)METHANONE; 1 (2 MERCAPTO 3 METHOXY 5 NITROPHENYL)ETHANONE; 1 (2 MERCAPTO 4 METHOXY 5 NITROPHENYL)ETHANONE; 1 (2 MERCAPTO 5 NITROPHENYL)ETHANONE; 2 BROMO N[2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]THIEN 5 YL]ACETAMIDE; 2 CHLORO N[7 METHOXY 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]THIEN 5 YL]ACETAMIDE; 2 MERCAPTO 3 METHOXY 5 NITROBENZALDEHYDE; 2 MERCAPTO 5 NITROBENZALDEHYDE; ANTIMITOTIC AGENT; BENZOTHIOPHENE DERIVATIVE; N[7 METHOXY 2 (3,4,5 TRIMETHOXYBENZOYL) 1 BENZO[B]THIEN 5 YL]ACETAMIDE; O 2 ACETYL 4 NITRO 5 METHOXYPHENYL N,N DIMETHYLCARBAMOTHIOATE; O 2 ACETYL 4 NITRO 6 METHOXYPHENYL N,N DIMETHYLCARBAMOTHIOATE; O 2 ACETYL 4 NITROPHENYL N,N DIMETHYLCARBAMOTHIOATE; O 2 FORMYL 4 NITRO 6 METHOXYPHENYL N,N DIMETHYLCARBAMOTHIOATE; O 2 FORMYL 4 NITROPHENYL N,N DIMETHYLCARBAMOTHIOATE; S 2 ACETYL 4 NITRO 5 METHOXYPHENYL N,N DIMETHYLCARBAMOTHIOATE; S 2 ACETYL 4 NITRO 6 METHOXYPHENYL N,N DIMETHYLCARBAMOTHIOATE; S 2 ACETYL 4 NITROPHENYL N,N DIMETHYLCARBAMOTHIOATE; S 2 FORMYL 4 NITROPHENYL N,N DIMETHYLCARBAMOTHIOATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; MICROTUBULE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OSTEOSARCOMA CELL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMITOTIC AGENTS; APOPTOSIS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; COLCHICINE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MITOCHONDRIA; MODELS, MOLECULAR; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTO-ONCOGENE PROTEINS C-BCL-2; THIOPHENES; TUBULIN; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84889247207     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4013938     Document Type: Article

References (53)

1. Amos, L. A. Microtubule structure and its stabilisation Org. Biomol. Chem. 2004, 2, 2153-2160
2. Walczak, C. E. Microtubule dynamics and tubulin interacting proteins Curr. Opin. Cell. Biol. 2000, 12, 52-56 (Pubitemid 30095269)
3. Downing, K. H.; Nogales, E. Tubulin structure: insights into microtubule properties and functions Curr. Opin. Struct. Biol. 1998, 8, 785-791 (Pubitemid 29004677)
4. Dumontet, C.; Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics Nature Rev. Drug. Discovery 2010, 9, 790-803
5. Chen, S.-M.; Meng, L.-H.; Ding, J. New microtubule-inhibiting anticancer agents Expert Opin. Invest. Drugs 2010, 3, 329-343
6. Pasquier, E.; Kavallaris, M. Microtubules: a dynamic target in cancer therapy IUBMB Life 2008, 60, 165-170
7. Hamel, E. An overview of compounds that interact with tubulin and their effects on microtubule assembly. In The Role of Microtubules in Cell Biology, Neurobiology and Oncology; Fojo, T., Ed.; Human Press: Totowa, NJ, 2008; pp 1-19.
8. Carlson, R. O. New tubulin targeting agents currently in clinical development Expert Opin. Invest. Drugs 2008, 17, 707-722 (Pubitemid 351843615)
9. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experentia 1989, 45, 209-211 (Pubitemid 19062390)
10. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin Biochemistry 1989, 28, 6984-6991 (Pubitemid 19219888)
11. Patterson, D. M.; Rustin, G. J. S. Combretastatin A-4 phosphate Drugs Future 2007, 32, 1025-1032
12. Petit, I.; Karajannis, M. A.; Vincent, L.; Young, L.; Butler, J.; Hopper, A. T.; Shido, K.; Steller, H.; Chaplin, D. J.; Feldman, E.; Rafi, S. The microtubule-targeting agent CA-4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death Blood 2008, 111, 1951-1961 (Pubitemid 351451505)
13. Siemann, D. W.; Chaplin, D. J.; Walike, P. A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opin. Invest. Drugs 2009, 18, 189-197
14. Rustin, G. J.; Shreeves, G.; Nathan, P. D.; Gaya, A.; Ganesan, T. S.; Wang, D.; Boxall, J.; Poupard, L.; Chaplin, D. J.; Stratford, M. R. L.; Balkissoon, J.; Zweifel, M. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer Br. J. Cancer 2010, 102, 1355-1360
15. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Lopez-Cara, C.; Preti, D.; Fruttarolo, F.; Pavani, M. G.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Di Antonella, C.; Balzarini, J.; Hadfield, J. A.; Brancale, A.; Hamel, E. Synthesis and biological evaluation of 2- and 3-aminobenzo[ b ]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization J. Med. Chem. 2007, 50, 2273-2277 (Pubitemid 46683083)
16. Jiang, J.-D.; Roboz, J.; Weisz, I.; Deng, L.; Ma, L.; Holland, J. F.; Bekesi, J. G. Synthesis, cancericidal and antimicrotubule activities of 3-(halocetamido)-benzoylureas Anti-Cancer Drug Des. 1998, 13, 735-747 (Pubitemid 28463999)
17. Song, D. Q.; Wang, Y.; Wu, L. Z.; Yang, P.; Wang, Y. M.; Gao, L. M.; Li, Y.; Qu, J. R.; Wang, Y. H.; Li, Y. H.; Du, N. N.; Han, Y. X.; Zhang, Z. P.; Jiang, J. D. Benzoylurea derivatives as a novel class of antimitotic agents: synthesis, anticancer activity and structure-activity relationships J. Med. Chem. 2008, 51, 3094-3103 (Pubitemid 351821870)
18. Luduena, R. F.; Roach, M. C. Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents Pharmacol. Ther. 1991, 49, 133-152
19. Hargreaves, A. J.; Glazier, A. P.; Flaskos, J.; Mullins, F. H.; Mcan, W. G. The disruption of brain microtubules in vitro by the phospholipase inhibitor p -bromophenacyl bromide Biochem. Pharmacol. 1994, 47, 1137-1143 (Pubitemid 24127926)
20. Beria, I.; Baraldi, P. G.; Cozzi, P.; Caldarelli, M.; Geroni, C.; Marchini, S.; Mongelli, N.; Romagnoli, R. Cytotoxic α-halogenoacrylic derivatives of distamycin A and congeners J. Med. Chem. 2004, 47, 2611-2623 (Pubitemid 38580097)
21. Banks, C. K.; Hamilton, C. S. Arsenated derivatives of mixed ketones. II. Arsenicals of peonol J. Am. Chem. Soc. 1938, 60, 1370-1371
22. Horton, W. J.; Spence, J. T. Hydrogen bromide cleavage of hindered 2′-methoxyacetophenones J. Am. Chem. Soc. 1958, 80, 2453-2456
23. For a review on the mechanism and application of Newman-Kwart rearrangement see: Lloyd-Jones, G. C.; Moseley, J. D.; Renny, J. S. Mechanism and application of the Newman-Kwart O-S rearrangement of O -aryl thiocarbamates Synthesis 2008, 5, 661-689 (Pubitemid 351397546)
24. Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin Cell Biochem. Biophys. 2003, 38, 1-21 (Pubitemid 41270819)
25. Hiser, L.; Aggarwal, A.; Young, R.; Frankfurter, A.; Spano, A.; Correia, J. J.; Lobert, S. Comparison of β-tubulin mRNA and protein levels in 12 human cancer cell lines Cell Motil. Cytoskeleton 2006, 63, 41-52 (Pubitemid 43157644)
26. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells Mol. Pharmacol. 1998, 53, 62-67
27. Massarotti, A.; Coluccia, A.; Silvestri, R.; Sorba, G.; Brancale, A. The tubulin colchicine domain: a molecular modeling perspective ChemMedChem 2012, 7, 33-42
28. Clarke, P. R.; Allan, L. A. Cell-cycle control in the face of damage-a matter of life or death Trends Cell Biol. 2009, 19, 89-98
29. Kiyokawa, H.; Ray, D. In vivo roles of Cdc25 phosphatases: biological insight into the anti-cancer therapeutic targets Anticancer Agents Med. Chem. 2008, 8, 832-836
30. Donzelli, M.; Draetta, G. F. Regulating mammalian checkpoints through cdc25 inactivation EMBO Rep. 2003, 4, 671-677 (Pubitemid 36974751)
31. Quignon, F.; Rozier, L.; Lachages, A. M.; Bieth, A.; Simili, M.; Debatisse, M. Sustained mitotic block elicits DNA breaks: one step alteration of ploidy and chromosome integrity in mammalian cells Oncogene 2007, 26, 165-172 (Pubitemid 46095728)
32. Ganem, N. J.; Pellman, D. Linking abnormal mitosis to the acquisition of DNA damage J. Cell Biol. 2012, 199, 871-881
33. Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V J. Immunol. Methods 1995, 184, 39-51
34. m) in apoptosis: an update Apoptosis 2003, 8, 115-128 (Pubitemid 36553052)
35. Green, D. R.; Kroemer, G. The pathophysiology of mitochondrial cell death Science 2004, 305, 626-629 (Pubitemid 39006738)
36. Mollinedo, F.; Gajate, C. Microtubules, microtubule-interfering agents and apoptosis Apoptosis 2003, 8, 413-450 (Pubitemid 37247987)
37. Chiang, N. J.; Lin, C.I.; Liou, J. P.; Kuo, C. C.; Chang, C. Y.; Chen, L. T.; Chang, J. Y. A novel synthetic microtubule inhibitor, MPT0B214, exhibits antitumor activity in human tumor cells through mitochondria-dependent intrinsic pathway Plos One 2013, 8, 58953
38. Romagnoli, R.; Baraldi, P. G.; Lopez-Cara, C.; Kimatrai Salvador, M.; Preti, D.; Aghazadeh Tabrizi, M.; Bassetto, M.; Brancale, A.; Hamel, E.; Castagliuolo, I.; Bortolozzi, R.; Basso, G.; Viola, G. Synthesis and biological evaluation of 2-alkoxycarbonyl-3-anilino benzo[ b ]thiophenes and thieno[2,3- b ]pyridines as new potent anticancer agents J. Med. Chem. 2013, 56, 2606-2618
39. Cai, J.; Jones, D. P. Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss J. Biol. Chem. 1998, 273, 11401-11404 (Pubitemid 28272028)
40. Nohl, H.; Gille, L.; Staniek, K. Intracellular generation of reactive oxygen species by mitochondria Biochem. Pharmacol. 2005, 69, 719-723 (Pubitemid 40248614)
41. Rothe, G.; Valet, G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′- dichlorofluorescein J. Leukocyte Biol. 1990, 47, 440-448 (Pubitemid 20155877)
42. Denault, J.-B.; Salvesen, G. S. Caspases: keys in the ignition of cell death Chem. Rev. 2002, 102, 4489-4499
43. Porter, A. G.; Janicke, R. U. Emerging role of caspase-3 in apoptosis Cell Death Differ. 1999, 6, 99-104
44. García-Sáez, A. J. The secrets of the Bcl-2 family Cell Death Differ. 2012, 19, 1733-1740
45. Haldar, S.; Basu, A.; Croce, C. M. Bcl2 is the guardian of microtubule integrity Cancer Res. 1997, 57, 229-233 (Pubitemid 27038278)
46. Poruchynsky, M. S.; Wang, E. E.; Rudin, C. M.; Blagosklonny, M. V.; Fojo, T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption Cancer Res. 1998, 58, 3331-3338 (Pubitemid 28371073)
47. Dubrez-Daloz, L.; Dupoux, A.; Cartier, J. IAPs: more than just inhibitors of apoptosis proteins Cell Cycle 2008, 7, 1036-1046
48. Romagnoli, R.; Baraldi, P. G.; Lopez Cara, C.; Kimatrai Salvador, M.; Bortolozzi, R.; Basso, G.; Viola, G.; Balzarini, J.; Brancale, A.; Fu, X.-H.; Li, J.; Zhang, S.-Z.; Hamel, E. One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3′,4′,5′-trimethoxybenzoyl)thiazole: an unique highly active antimicrotubule agent Eur. J. Med. Chem. 2011, 46, 6015-6024
49. Viola, G.; Vedaldi, D.; Dall'Acqua, F.; Fortunato, E.; Basso, G.; Bianchi, N.; Zuccato, C.; Borgatti, M.; Lampronti, I.; Gambari, R. Induction of γ-globin mRNA, erythroid differentiation and apoptosis in UVA-irradiated human erythroid cells in the presence of furocoumarin derivatives Biochem. Pharmacol. 2008, 75, 810-825 (Pubitemid 351174109)
50. Porcù, E.; Viola, G.; Bortolozzi, R.; Mitola, S.; Ronca, R.; Presta, M.; Persano, L.; Romagnoli, R.; Baraldi, P. G.; Basso, G. TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis Angiogenesis 2013, 16, 647-662
51. Dorleans, A.; Gigant, B.; Ravelli, R. B.; Mailliet, P.; Mikol, V.; Knossow, M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 13775-13779
52. Molecular Operating Environment (MOE 2010); Chemical Computing Group, Inc: Montreal, Quebec, Canada, 2010; http://www.chemcomp.com.
53. Korb, O.; Stützle, T.; Exner, T. E. PLANTS: Application of ant colony optimization to structure-based drug design. In Ant Colony Optimization and Swarm Intelligence, 5th International Workshop, ANTS 2006, Brussels, Belgium, Sep 4-7, 2006; Dorigo, M.; Gambardella, L. M.; Birattari, M.; Martinoli, A.; Poli, R.; Sttzle, T., Eds.; Springer: Berlin, 2006; LNCS 4150, pp 247-258. (Pubitemid 44811953)